BS_N210XMKR
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 40.14454664914586
- age_years
- 12.159
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.515
- OXIDATIVE_PHOSPHORYLATION+0.457
- ADIPOGENESIS+0.368
- ANDROGEN_RESPONSE+0.355
- BILE_ACID_METABOLISM+0.280
- FATTY_ACID_METABOLISM+0.264
- INTERFERON_ALPHA_RESPONSE+0.221
- UNFOLDED_PROTEIN_RESPONSE+0.221
- PEROXISOME+0.213
- XENOBIOTIC_METABOLISM+0.149
Top 10 suppressed
- E2F_TARGETS-0.381
- G2M_CHECKPOINT-0.358
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.286
- MYC_TARGETS_V2-0.189
- INFLAMMATORY_RESPONSE-0.180
- KRAS_SIGNALING_DN-0.173
- HYPOXIA-0.129
- PANCREAS_BETA_CELLS-0.105
- TNFA_SIGNALING_VIA_NFKB-0.094
- GLYCOLYSIS-0.092
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_DPF1CX0G | pilocytic astrocytoma | — | 0.846 |
| 2 | BS_17WYVEEC | pilocytic astrocytoma | — | 0.832 |
| 3 | BS_Y0PCBNJV | pilocytic astrocytoma | — | 0.807 |
| 4 | SRR15030845 | — | — | 0.792 |
| 5 | BS_GHNJ4CYC | low-grade glioma | — | 0.791 |
| 6 | BS_52DAPP1Y | low-grade glioma | — | 0.783 |
| 7 | e59f49c0-d7ce-44c3-9590-9b65128d7f8b | — | — | 0.778 |
| 8 | BS_3Q0GTSYH | pilocytic astrocytoma | — | 0.776 |
| 9 | BS_RGSMX7QD | Ganglioglioma | — | 0.776 |
| 10 | s_150324_8c | EPN | Posterior Fossa EPN | 0.772 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.515 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.457 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.368 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.355 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.264 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.221 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.221 | Idelalisib | — uncovered |
| PEROXISOME | 0.213 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.149 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.148 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.136 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.134 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.122 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.117 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.114 | Idelalisib | — uncovered |
| COMPLEMENT | 0.094 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.091 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.081 | Idelalisib | — uncovered |